Dimitrios Bouzianas

Dr. Dimitrios Bouzianas

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2013 in Nutrition Reviews
Verified
Journal Article
Closed access
PDF file
DBDimitrios Bouzianas
Dimitrios Bouzianas
SBStella D Bouziana
Stella D Bouziana
AHApostolos I Hatzitolios
Apostolos I Hatzitolios

Verified
Journal Article
Open access
PDF file
SBStella Bouziana
Stella Bouziana
DBDimitrios Bouzianas
Dimitrios Bouzianas
Chimeric antigen receptor (CAR) T-cell therapies have revolutionised the field of haematological malignancies by achieving impressive remission rates in patients with highly refractory haematological malignancies, improving overall survival. To date, six commercial anti-CD19 and anti-BCMA CAR T-cell products have been approved by the Food and Drug Administration (FDA) for the treatment of relapsed/refractory B-cell haematological malignancies and multiple myeloma. The indications for CAR T-cell therapies are gradually expanding, with these therapies being investigated in a variety of diseases, including non-malignant ones. Despite the great success, there are several challenges surrounding CAR T-cell therapies, such as non-durable responses and high-grade toxicities. In addition, a new safety concern was added by the FDA on 28 November 2023 following reports of T-cell malignancies in patients previously treated with either anti-CD19 or anti-BCMA autologous CAR T-cell therapies both in clinical trials and in the real-world setting. Since then, several reports have been published presenting the incidence and analysing the risks of other secondary malignancies after CAR T-cell therapies. In this opinion article, the current landscape of secondary malignancies after CAR T-cell therapies is presented, along with a proposed strategy for future research aiming at potentially diminishing or abrogating the risk of developing secondary malignancies after CAR T-cell therapies.


19 June 2025 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
DBDimitrios Bouzianas
Dimitrios Bouzianas
SBStella Bouziana
Stella Bouziana

31 October 2023 in Exploration of Targeted Anti-tumor Therapy
Verified
Journal Article
Open access
PDF file
DBDimitrios Bouzianas
Dimitrios Bouzianas
SBStella Bouziana
Stella Bouziana
On Feb 2, 2022, Nature published the paper titled “Decade-long leukemia remissions with the persistence of CD4+ CAR T-cells” (Nature. 2022;602:503–9. doi: 10.1038/s41586-021-04390-6). Accordin

26 June 2024
Verified
Book Chapter
Open access
PDF file
DBDimitrios Bouzianas
Dimitrios Bouzianas
In Western countries, age-related macular degeneration (AMD) is the common cause of central visual loss in the elderly leading to gradual blindness. Studies implicate the retinal pigment epithelium (RPE) as an important player in AMD pathogenesis, as progressive loss of RPE cells and photoreceptors lead to poor visual acuity. Several strategies aim to prevent the RPE degeneration by saving the damaged retinal cells or replacing them. Cell rescue provides retinal cells with trophic or immunomodulatory factors, whereas cell replacement aims to repair and regenerate neuroretina providing new cells. Currently, a major limitation is cell loss from subretinal injections of bolus cell suspensions. The most promising studies focus on tissue transplantation or RPE cell patches hosted on implantable scaffolds made of advanced biomaterials. The latter support the development of artificial 3D retinal constructs improving functional integration capacity and increasing the survival of implanted cells into the damaged retina. However, there is no consensus on the optimal RPE source, delivery strategy, cell dose and animal model for testing. This chapter aims to improve the efficacy of RPE grafting suggesting an optimal cell source, an efficient delivery method, and the topography of retina damage as a determining factor to calculate the effective therapeutic dose.